基于CRISPR/Cas9的双链寡核酸插入策略纠正了小鼠糖原储存疾病类型Ia的代谢异常
Ananya Samanta1, Nelson George1, Irina Arnaoutova1
1Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
Journal of inherited metabolic disease
|July 19, 2023
概括
通过CRISPR/Cas9基因编辑,纠正了G6pc-R83C突变,这种突变发生在一种患有糖原储存疾病类型Ia (GSD-Ia) 的小鼠模型中. 这种方法恢复了葡萄糖平衡和正常化代谢物,提供了潜在的永久治疗策略.
科学领域:
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 糖原储存疾病类型-Ia (GSD-Ia) 由葡萄糖-6-酸酶-α (G6Pase-α) 缺乏引起,导致血糖稳定性受损.
- 在G6pc-R83C小鼠模型中,重新总结了人类GSD-Ia的关键特征.
研究的目的:
- 研究一种基于CRISPR/Cas9的基因编辑策略,使用双链DNA寡核酸 (dsODN) 来纠正GSD-Ia小鼠中的G6pc-R83C突变.
- 评估这种通过脂质纳米颗粒 (LNP) 传递到肝脏的插入编辑策略的治疗潜力.
主要方法:
- 使用dsODN插入策略来破坏突变的G6pc外子-2并通过非同类末端连接修复引入纠正序列.
- 编辑试剂在LNP中配制,并送入不同年龄和剂量的G6pc-R83C小鼠的肝脏.
- 治疗后评估了肝脏G6Pase-α活性,葡萄糖稳定性和血液代谢物概况.
主要成果:
- 在接受治疗的小鼠中,成功的基因编辑导致大约4%的正常肝G6Pase-α活性.
- 经过编辑的小鼠表现出正常化的血糖水平,没有低血糖发作,并纠正了血液代谢物概况.
- 在一次或两次LNP-dsODN剂量后观察到治疗效果,表明有效性.
结论:
- 通过CRISPR/Cas9介导的dsODN插入编辑,可以在小鼠模型中纠正GSD-Ia表型.
- 这一策略为GSD-Ia提供了潜在的治疗方法,与基因增强疗法相比,可以进行早期干预和永久纠正.
相关概念视频
01:59CRISPR
52.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.4K
01:28CRISPR/Cas9 Genome Editing
65
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
65